The engineered bone marrow mesenchymal stem cell-derived exosome: A new strategy for the treatment of inflammatory diseases
International Immunopharmacology · 2025-09 · 162 · 115136
DOI: 10.1016/j.intimp.2025.115136 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025-09. Verfasst von Xinyi Peng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endodontics, Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Exosomes, Mesenchymal Stem Cells, Inflammation, Mesenchymal Stem Cell Transplantation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 171 Literaturangaben. Gefördert von: Southern Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Inflammatory diseases are characterized by chronic inflammation as the underlying pathogenic mechanism. Current treatments primarily rely on anti-inflammatory and glucocorticoid drugs to suppress inflammation, but these approaches often provide only symptomatic relief without promoting tissue repair. Bone marrow mesenchymal stem cells (BMSCs) have demonstrated significant therapeutic potential in inflammatory diseases due to their immunomodulatory properties, ability to promote tissue regeneration, and secretion of various bioactive factors. Recent studies have shown that BMSC-derived exosomes (BMSC-EXOs) possess similar therapeutic functions while overcoming several limitations associated with cell-based therapies, including ethical concerns, immunogenicity, and challenges related to in vitro culture and expansion. Furthermore, engineering strategies have enhanced the cargo capacity, targeting specificity, and circulation time of BMSC-EXOs, thereby improving their therapeutic efficacy in inflammatory conditions. This review summarizes the isolation methods, biological functions, and engineering approaches of BMSC-EXOs in the context of inflammatory diseases, aiming to inform future diagnostic and therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endodontics, Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, China.
- Department of Endodontics, Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, China. Electronic address: ntt11@foxmail.com.
- Department of Endodontics, Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, China. Electronic address: mdd@smu.edu.cn.
Förderung
- Southern Medical University
- National Natural Science Foundation of China
Zitieren
APA
Peng, X., Cui, H., Tan, S., Wen, B., Luo, X., Chen, S., Luo, J., Zhong, P., Ning, T., & Ma, D. (2025). The engineered bone marrow mesenchymal stem cell-derived exosome: A new strategy for the treatment of inflammatory diseases. International Immunopharmacology, 162, 115136. https://doi.org/10.1016/j.intimp.2025.115136
Vancouver
Peng X, Cui H, Tan S, Wen B, Luo X, Chen S, et al. The engineered bone marrow mesenchymal stem cell-derived exosome: A new strategy for the treatment of inflammatory diseases. International Immunopharmacology. 2025;162:115136. doi:10.1016/j.intimp.2025.115136
BibTeX
@article{Peng2025,
author = {Peng, Xinyi and Cui, Hao and Tan, Shenglong and Wen, Bo and Luo, Xinghong and Chen, Shuoling and Luo, Jiayu and Zhong, Peiliang and Ning, Tingting and Ma, Dandan},
title = {The engineered bone marrow mesenchymal stem cell-derived exosome: A new strategy for the treatment of inflammatory diseases},
journal = {International Immunopharmacology},
year = {2025},
volume = {162},
pages = {115136},
doi = {10.1016/j.intimp.2025.115136}
}
EUVIMED